Novo Nordisk Faces Mounting Pressure as Legal and Competitive Challenges Intensify

The battle for dominance in the lucrative weight-loss medication sector has entered a critical new phase. Pharmaceutical giant Pfizer has escalated its offensive against Novo Nordisk by filing a second antitrust lawsuit, strategically timed just one day before the Danish company’s highly anticipated quarterly earnings release. This legal maneuver raises significant questions about Novo Nordisk’s ability to defend its market position against increasingly aggressive competition.

In a dramatic legal move on Monday, Pfizer submitted an additional antitrust complaint to the U.S. District Court in Delaware. The lawsuit centers on Novo Nordisk’s unexpected $9 billion bid for biotechnology firm Metsera, which Pfizer alleges constitutes anti-competitive behavior designed to eliminate Read more...